Health Condition 1: - Health Condition 2: null- Grade III and grade IV lowerlimb lymphoedema in lymphatic filariasis
Conditions
Interventions
Intervention1: Homoeopathy: Individualised homoeopathic medicines for 01 year
Control Intervention1: Nil: Nil
Sponsors
Central Council for Research in Homoeopathy
Eligibility
Inclusion criteria
Inclusion criteria: 1.Subjects in the age group 18 ââ?¬â?? 99 years 2.Both male and female subjects 3.Subjects with grade III and grade IV unilateral/bilateral lowerlimb lymphoedema with clinical diagnosis/clinical history of lymphatic filariasis 4.inclusion of patient with controlled diabetes mellitus and controlled hypertension. 5.Subjects who have given the written informed consent
Exclusion criteria
Exclusion criteria: 1.Newly diagnosed cases with ADL attacks with grade I and grade II lymphadenopathy 2.Subjects having lymphoedema due to non filarial causes like congenital lymphoedema, deep vein thrombosis, malignancies, irradiation, surgery, podoconiosis etc. 3.History of known life threatening disease/systemic illness (tuberculosis,cancer, AIDS, uncontrolled diabetes, uncontrolled hypertension, cardiovascular disorders etc.) 4.Subjects taking lifelong medication for any other chronic illness. 5.Pregnant/lactating women 6.Subject deemed unfit by Investigator and Consultant
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.To assess and compare the clinical improvement in grade III and grade IV unilateral/bilateral lower limb lymphedema at the end of 01 year by a. Determining the changes in limb circumference using tape measure following the protocol described by the Australasian Lymphology Association(ALA) . b. Volume changes in lymphoedema by ââ?¬Ë?Water Displacement Methodââ?¬â?¢ Timepoint: Measurement of limb circumference- baseline,monthly till 12th month | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.To assess and compare QOL using 7D5L scale 2.To assess and compare Og4C3 and TNF-alfa 3.To assess and compare Dermatology Life Quality Index (DLQI) 4.To assess and compare ADL attacks at the end of one year treatment. 5.To assess and compare the changes in joint mobility 6.To assess and compare skin healthTimepoint: 1.7D5L scale - baseline,3rd,6th, 9th and 12th month 2.Og4C3 and TNF-alfa - baseline, 12th month 3.DLQI- baseline, 3rd,6th,9th and 12th month 4.ADL - baseline, monthly till 12th month 5.Changes in joint mobility-baseline,12th month 6. Skin health - baseline, monthly till 12th month | — |
Countries
India
Contacts
Public ContactDr Suhana P Azis
Central Council for Research in Homoeopathy
Outcome results
None listed